Für diesen Artikel ist leider kein Bild verfügbar.

Fibroblast Growth Factor 23

Christian Faul, Kenneth White, Orlando Gutierrez (Herausgeber)

Buch | Softcover

376 Seiten

2021
Elsevier Science Publishing Co Inc (Verlag)
978-0-12-818036-5 (ISBN)

Artikel merken

Fibroblast Growth Factor 23 describes how FGF23 was initially identified as a bone-derived factor targeting the kidney. As such, sections in this comprehensive book cover exciting research that shows that different FGF23 effects require distinct signaling receptors and mediators that differ among target tissues, cover FGF23 initially identified as a bone-derived factor targeting the kidney, look at FGF23 as a regulator of phosphate metabolism and beyond, and cover research on novel concepts of FGF receptor signaling. Additional sections cover biochemistry, pharmacology and nephrology, making this book an ideal reference source on FGF23.

Dr. Faul earned his PhD title at the Albert Einstein College of Medicine in the Bronx in 2005, and conducted his postdoctoral research training at the Mount Sinai School of Medicine in New York City. He currently is an Associate Professor in the Division of Nephrology within the Department of Medicine and in the Department of Cell, Developmental and Integrative Biology (CDIB) at UAB.) He is also a member of the Comprehensive Diabetes Center and Section of Cardio-Renal Physiology and Medicine. He focuses on circulating fibroblast growth factors and their pathological effects on the heart in the context of diabetes and chronic kidney disease. In collaborations with pharma industry, Dr. Faul analyzes beneficial cardiac effects of pharmacological blockers for fibroblast growth factor receptors in animal models with diabetes and kidney injury. Dr. Faul received research funding from the American Diabetes Association (ADA), the American Society of Nephrology (ASN), and American Heart Association (AHA), and the NephCure Foundation, as well as support from pharma industry. Dr. White studied the molecular genetics of metabolic bone diseases during an NIH-sponsored postdoctoral fellowship at the Indiana University School of Medicine (IUSM). He played an instrumental role in discovering the novel hormone FGF23 during this time, and since then his laboratory has been funded to study FGF23 and its co-receptor Klotho. Within the University, he is Director of the MMGE Division of Molecular Genetics and Gene Therapy and currently a member of the Indiana Center for Musculoskeletal Health (ICMH). Dr. Gutiérrez is the Hilda B. Anderson Endowed Chair in Nephrology, Professor of Medicine and Epidemiology, Associate Director of the Division of Nephrology, and Deputy Director of the Center for Clinical and Translational Science at the University of Alabama at Birmingham (UAB). Dr. Gutiérrez’s research is focused on understanding pathophysiological mechanisms underlying disorders of phosphorus and vitamin D metabolism in health and in individuals with kidney disease. He has a special interest in delineating environmental and/or behavioral factors that may modulate these associations, particularly those related to health disparities, poverty and nutrition. To this end, his group conducts epidemiologic and patient-oriented studies investigating the impact of disturbances in phosphorus metabolism on kidney and cardiovascular health. He is funded by grants from the National Institutes of Health, the American Heart Association, and industry.

1. The discovery of FGF23 – a historic view: genetic disorders of hypo- and hyperphosphatemia
2. FGF23 – an established master regulator of phosphate metabolism
3. FGF23 – more than a phosphaturic hormone
4. The regulation of FGF23 production in bone and outside of bone
5. Klotho-dependent actions of FGF23 - targets, signal transduction and cellular effects
6. Klotho-independent actions of FGF23 - targets, signal transduction and cellular effects
7. The experimental detection of FGF23 responsiveness and effects
8. FGF23 and bone disease
9. FGF23 and kidney disease
10. FGF23 and heart and vascular disease
11. FGF23 and inflammation, anemia, and iron
12. FGF23 and infectious diseases
13. FGF23 and lung disease
14. FGF23 and neuro-cognitive disorders
15. FGF23 as a drug target
16. FGF23 – resolved issues, remaining controversies and future questions – a clinician’s perspective
17. Klotho – the discovery of the FGF23 co-receptor
18. Klotho – an FGF23-independent hormone
19. Klotho and aging phenotypes
20. αKlotho gene and protein measurements in humans and their role as a clinical biomarker of disease
21. Structural Basis of FGF23 Hormone Signaling
22. Klotho – open questions, controversies and future perspectives
23. The crosstalk between phosphate, FGF23 and klotho in the regulation of tissue homeostasis in health and disease

Erscheinungsdatum	16.04.2021
Sprache	englisch
Maße	216 x 276 mm
Gewicht	1110 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Diabetologie
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie
ISBN-10	0-12-818036-6 / 0128180366
ISBN-13	978-0-12-818036-5 / 9780128180365
Zustand	Neuware